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MotivesBackground: In unselected elderly with stage III Non-Small Cell Lung Cancer (NSCLC), evidence is scarce
regarding motives and effects of treatment modalities.
Methods: Hospital-based multicenter retrospective study including unresectable stage III NSCLC patients
aged P70 and diagnosed between 2009 and 2013 (N = 216). Treatment motives and tolerance (no
unplanned hospitalizations and completion of treatment), and survival were derived from medical
records and the Netherlands Cancer Registry.
Results: Patients received concurrent chemoradiation (cCHRT, 33%), sequential chemoradiation (sCHRT,
24%), radical radiotherapy (RT, 16%) or no curative treatment (27%). Comorbidity, performance status
(58%) and patient refusal (15%) were the most common motives for omitting cCHRT. Treatment tolerance
for cCHRT and sCHRT was worse in case of severe comorbidity (OR 6.2 (95%CI 1.6–24) and OR 6.4 (95%CI
1.8–22), respectively). One-year survival was 57%, 50%, 49% and 26% for cCHRT, sCHRT, RT and no curative
treatment, respectively. Compared to cCHRT, survival was worse for no curative treatment (P = 0.000),
but not significantly worse for sCHRT and RT (P = 0.38).
Conclusion: Although relatively fit elderly were assigned to cCHRT, treatment tolerance was worse, espe-
cially for those with severe comorbidity. Survival seemed not significantly better as compared to sCHRT
or RT. Prospective studies in this vital and understudied area are needed.
 2016 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 121 (2016) 26–31Thirty percent of all Non-Small Cell Lung Cancer (NSCLC)
patients present with stage III disease [1,2]. A meta-analysis
including clinical trials showed the superiority of concurrent
chemoradiation (cCHRT) to sequential chemoradiation (sCHRT)
for unresectable stage III NSCLC, with a 2- and 5-year survival of
36% and 15% for cCHRT and 30% and 11% for sCHRT [2]. Mainly
fit patients with minimal or no comorbidity were included and
only 16% was aged P70. Nevertheless, cCHRT is considered stan-
dard treatment [2–5]. Alternative curative treatment options are
sCHRT [6–8] and radical radiotherapy (RT) [9,10]. Symptom relief
and preservation of quality of life (QoL) is offered to patients noteligible for curative options by palliative care or best supportive
care [7,11].
NSCLC is diagnosed at a median age of 70 years and the majority
of these patients are poor-risk, indicating poor characteristics for
treatment tolerance and prognosis [12,13]. Risk factors for poor
treatment tolerance include poor general performance status
(PS), polypharmacy, frailty, history of smoking, and extensive
smoking-related comorbidity. Other geriatric characteristics such
as living situation and functional disability can jeopardize treat-
ment outcomes even more [14–18]. As a result, severe adverse
events may occur more often, leading to reduced treatment dose,
treatment discontinuation, hospitalization or even death
[2,7,13,19]. In clinical trials, evidence for treatment regimens is
generally assessed in relatively fit and younger patients. These data
cannot be extrapolated to the heterogeneous group of NSCLC
E.J.M. Driessen et al. / Radiotherapy and Oncology 121 (2016) 26–31 27patients in clinical practice, resulting in lack of knowledge on treat-
ment administration for the elderly and poor-risk patients [12–
14,16,20]. In some studies, subset analyses among older patients
have been performed to provide information on treatment effects
[1,2,21]. However, small sample sizes (N < 50) lead to lack of solid
conclusions and the role of comorbidity, PS and other patient
characteristics on treatment tolerance and survival in the elderly
receiving chemoradiation (CHRT) remains uncertain
[7,12,16,22,23].
The aims of this study were to evaluate treatment strategies,
identify motives for omitting cCHRT and determine predictors for
treatment tolerance and survival in unselected elderly with unre-
sectable stage III NSCLC in daily clinical practice.Patients and methods
Patients were retrieved from the population-based Netherlands
Cancer Registry, where trained registrars collect data from patient
records like histology and stage of disease with a completeness
rate of 95% [24]. All patients from three Dutch teaching hospitals
were selected. Additional information on treatment motives,
patient characteristics, treatment tolerance and survival was retro-
spectively collected from the medical records. Inclusion criteria
were age P70 and a diagnosis of unresectable stage III NSCLC
between 2009 and 2013. This period was chosen because of the
new TNM staging guidelines in 2009 (TNM Lung Cancer Staging
7th edition [25]) and the ability to collect complete and good qual-
ity data retrospectively from medical records. Patients were
included from January 1st 2009 until December 31st 2013 and
follow-up (FU) was completed until January 31st 2015. Data han-
dling of the unidentifiable data from the Netherlands Cancer Reg-
istry was done according to the specifications of the officially
recognized Code of Conduct Use of data in health research [26].
Due to the retrospective design, study approval by the medical
ethics committee was not mandatory according to the Dutch law
‘Medical Research (human subjects) Act’ [27]. The following
patient characteristics were categorized: Age in years (70–74,
75–79 and 80+), Body Mass Index (BMI) in kg/m2 (<22, 22–28
and >28) [28], histology (adenocarcinoma, squamous cell carci-
noma or large cell/Not Otherwise Specified (NOS)), comorbidity
according to the Adult Comorbidity Evaluation 27 (ACE-27) (severe
comorbidity (severe decompensation in one organ or moderate
decompensation in P2 organs) and no severe comorbidity (no
decompensation, mild decompensation in one organ, moderate
decompensation in one organ or mild decompensation in P2
organs)), number of comorbid conditions (0, 1 or P2) and type
of comorbidity (cardiovascular, respiratory or renal) [29], World
Health Organization Performance Status (WHO PS) (0–1 and P2)
and smoking (current, former and never). Social factors were coded
as living independently (yes/no) and living alone (yes/no). Motives
for omitting cCHRT were categorized as comorbidity and/or PS,
refusal by patient, short life expectancy, high age and other.
Planned treatment options were classified as cCHRT, sCHRT, RT
or no curative treatment (including palliative chemotherapy (CT),
palliative RT and no active treatment). Regimens for CT consisted
of two or three concurrent cis- or carboplatin based doublet cycles
or three to four sequential cis- or carboplatin based doublet cycles.
Platinum partner CT and number of cycles depended on local hos-
pital protocol. For RT, Gross Tumor Volume (GTV) included the pri-
mary tumor and pathologic lymph nodes as identified on the FDG-
PET scan. During the period 2009–2011, Intensity Modulated
Radiotherapy (IMRT) was used, and from 2012 radiotherapy was
delivered with an arc technique. Volume constraints for the esoph-
agus were not performed, the maximum point dose in the esopha-
gus was 76 Gy (biologically equivalent dose in 2 Gy fractions(EQD2)). The Clinical Target Volume (CTV) covered an extra margin
to include regions at risk of microscopic extension. Planning Target
volume (PTV) encompassed a margin for inter- and intrafraction
patient and organ motion. Radical RT was defined as delivery of a
minimum total tumor dose (TTD) of 54 Gy (EQD2). Possible RT
schedules included 33 * 2 Gy (once daily), 24 * 2.75 Gy (once daily)
or RT according to an individualized prescribed maximal tolerated
dose protocol (once or twice daily). RT was delivered using 6–10
MV photons. The dose was specified at 100% in the ICRU reference
point. The dose gradient was 95–115%. Completion of CHRT was
determined by receiving a minimal radiation dose of 54 Gy com-
bined with all planned CT cycles. Completion of RT was achieved
when receiving a radiation dose of at least 54 Gy. Treatment toler-
ance (yes/no) was classified as completion of treatment combined
with no unplanned hospitalizations, including hospitalizations for
acute radiation esophagitis. Since unplanned hospitalizations are
more expected and accepted during cCHRT [2,6], separate analyses
were performed for ‘completion of treatment’ as a measure for
treatment tolerance. Overall Survival (OS) was calculated from
date of diagnosis of stage III NSCLC until death or until last date
of FU and censored. The Consolidated Standards of Reporting Trials
(CONSORT) flow-diagram is displayed in Supplemental Fig. 1.Statistical analyses
Statistical analyses were performed with IBM SPSS Statistics 22.
Patient characteristics were described according to treatment reg-
imen (cCHRT, sCHRT, RT or no curative treatment) and significant
differences between treatment regimens were assessed by v2-
test, Fisher’s exact test, or ANOVA (P < 0.05 two sided). Motives
for omitting cCHRT were described (N and %). Univariate and mul-
tivariate binary logistic regression analyses were performed for
treatment tolerance and patient characteristics. The Odds Ratio
(OR) and corresponding 95% Confidence Intervals (95%CI) were dis-
played. Worse treatment tolerance was indicated by OR > 1.0. For
regression analysis, the backward stepwise method was used with
an entry probability of 0.05 and removal of 0.10. It was assumed
that treatment choice partially depended on patient characteristics
(‘confounding by indication’). Therefore, analyses for treatment
tolerance and survival were stratified according to treatment regi-
men. Kaplan–Meier analyses were performed to assess median OS
and significant differences between groups were assessed by the
log rank test (P < 0.05). Median follow-up was estimated with the
reverse Kaplan–Meier method [30]. The Hazard Ratio (HR) and
95%CI were calculated by Cox regression analyses for survival
and patient characteristics. Worse survival was indicated by
HR > 1.0. In all multivariate analyses, outcomes were determined
significant if the 95%CI was completely above or below 1.0.Results
A total of 216 elderly patients with unresectable stage III NSCLC
were included. Seventy-two received cCHRT (33%), 52 received
sCHRT (24%), 34 received RT (16%) and 58 received no curative
treatment (27%). In Table 1, patient characteristics according to
administered treatment are shown. Age P75, PSP 2 and severe
comorbidity were significantly more present in patients not receiv-
ing cCHRT (P < 0.05). The most common motives for omitting
cCHRT were the presence of comorbidity, a poor PS or a combina-
tion of both (57%), and refusal by the patient (15%). Other motives
were short life expectancy (11%), high age (4%) and other/unknown
(12%).
Most patients completed administered treatment (71%, 63% and
80% for cCHRT, sCHRT and RT, respectively (P = 0.26)). Surprisingly,
only 26% of patients receiving cCHRT tolerated treatment (defined
Fig. 1. Percentage of patients tolerating treatment (completion of treatment and no
unplanned hospitalizations) per treatment and comorbidity group, abbreviations:
cCHRT ‘concurrent chemoradiation’, sCHRT ‘sequential chemoradiation’, RT ‘radical
radiotherapy’, NS ‘ Not Significant’.
Table 2
Odds Ratios (ORs) for predictors of treatment tolerance stratified for cCHRT and










75–79 0.69 (0.22–2.2) 0.52 NA
80+ 0.70 (0.15–3.3) 0.65
WHO PS
0–1 Reference
2–3 NA 0.99 NA
Comorbidity
No severe Reference Reference




75–79 1.1 (0.26–4.3) 0.92 NA
80+ 0.33 (0.08–1.5) 0.15
WHO PS
0–1 Reference
2–3 2.2 (0.59–8.2) 0.24 NA
Comorbidity
No severe Reference Reference
Severe 5.6 (1.6–23) 0.006 6.4 (1.8–22) 0.004
Figures are displayed as OR (95%CI) ‘Odds Ratio (95% Confidence Interval)’, abbre-
viations: cCHRT ‘concurrent chemoradiation’, NA ‘Not Applicable’, sCHRT ‘sequen-
tial chemoradiation’, WHO PS ‘World Health Organization Performance Status’,
OR > 1.0 indicates worse treatment tolerance, none of the unadjusted predictors
was significant for radical radiotherapy.
Table 1
Overview of patient characteristics according to administered treatment.
N(%) cCHRT sCHRT RT NCT P-value
72 (33) 52 (24) 34 (16) 58 (27)
Gender 0.58
Male 55 (76) 44 (85) 26 (77) 43 (74)
Female 17 (24) 8 (15) 8 (24) 15 (26)
Age (years) 0.000
70–74 39 (54) 15 (29) 3 (9) 18 (31)
75–79 23 (32) 22 (42) 14 (41) 21 (36)
80+ 10 (14) 15 (29) 17 (50) 19 (33)
WHO PS 0.000
0–1 69 (96) 36 (69) 20 (59) 17 (29)
2–3 2 (3) 15 (29) 14 (41) 38 (66)
Unknown 1 (1) 1 (2) 0 (0) 3 (5)
Comorbidity 0.000
No severe 41 (57) 20 (39) 12 (35) 15 (26)
Severe 31 (43) 30 (62) 22 (65) 43 (74)
Comorbidity N 0.05
0 13 (18) 9 (17) 2 (6) 5 (9)
1 22 (30) 8 (15) 10 (29) 9 (16)
P2 37 (51) 35 (67) 22 (65) 44 (76)
Type⁄⁄
Cardiovascular 43 (60) 36 (69) 24 (71) 43 (74) 0.84
Respiratory 16 (22) 20 (38) 10 (29) 23 (40) 0.23
Renal 4 (6) 2 (4) 1 (3) 4 (7) 0.66
BMI (kg/m2) 0.83
<22 10 (14) 5 (10) 4 (12) 8 (14)
22–28 42 (58) 33 (64) 15 (44) 29 (50)
>28 20 (28) 14 (27) 11 (32) 11 (19)
Unknown 0 (0) 0 (0) 4 (12) 10 (17)
Smoking 0.73
Current 29 (40) 18 (35) 9 (27) 22 (38)
Former 39 (54) 33 (64) 16 (47) 26 (45)
Never 2 (3) 1 (2) 2 (6) 3 (5)
Unknown 2 (3) 0 (0) 7 (21) 7 (12)
Histology 0.2
Squamous CC 23 (32) 15 (30) 5 (15) 15 (26)
Adenocarcinoma 17 (24) 7 (14) 7 (21) 17 (29)
NOS/large CC 32 (44) 28 (56) 22 (65) 26 (45)
Living independent 0.19
Independent 68 (96) 49 (94) 27 (79) 44 (76)
Dependent 3 (4) 3 (6) 4 (12) 7 (12)
Unknown 1 (1) 0 (0) 3 (9) 7 (12)
Living alone 0.36
Alone 31 (43) 18 (35) 13 (38) 27 (47)
Not alone 40 (56) 34 (65) 16 (47) 25 (43)
Unknown 1 (1) 0 (0) 5 (15) 6 (10)
Platinum type 0.1
Carboplatin 29 (40) 25 (48) NA NA
Cisplatin 42 (58) 19 (37)
Unknown 1 (1) 8 (15)
Figures are displayed as N (%) ‘Number (percentage)’, the P-value is based on known
data, abbreviations: CC ‘Cell Carcinoma’, cCHRT ‘concurrent chemoradiation’,
NA ‘Not Applicable’, NCT ‘No Curative Treatment’, NOS ‘Not Otherwise Specified’,
sCHRT ‘sequential chemoradiation’, RT ‘radical radiotherapy’, WHO PS ‘World
Health Organization Performance Status’, **comorbidity type: mild, moderate and
severe comorbidities combined, the percentage could exceed 100% since >60% of
patients have P2 comorbidities.
28 Treatment effects in stage III NSCLC P70as completed treatment without unplanned hospitalizations) com-
pared to 40% for sCHRT and 59% for RT (P = 0.000). Additionally,
patients undergoing CHRT with severe comorbidity had signifi-
cantly worse treatment tolerance compared to patients without
severe comorbidity (OR 6.2 (95%CI 1.6–24) for cCHRT and OR 6.4
(95%CI 1.8–22) for sCHRT, Fig. 1 and Table 2). The same trend
was seen in patients with P2 comorbid conditions compared to
no comorbidity (OR 7.1 (95%CI 1.6–32) for cCHRT and OR 6.5
(95%CI 1.3–32) for sCHRT). No other significant associations
between treatment tolerance and characteristics were found.Overall median FU was 47 months. Median OS and 1- and 2-
year survival for cCHRT were 18 months (95%CI 9.2–27), 57% and
21%, respectively (Fig. 2). For sCHRT, this was 12 months (95%CI
7.5–17), 50% and 17%, respectively. For RT, these figures were
11 months (95%CI 5.5–16), 49% and 14%, respectively, and for no
curative treatment 5 months (95%CI 1.6–8.4), 26% and 4%, respec-
tively. In multivariate analyses, OS for patients who received no
curative treatment was significantly worse compared to those
who received curative treatment options (HR 2.9 (95%CI 1.9–4.3)
P = 0.000). However, cCHRT did not show significant superior OS
compared to sCHRT or RT (HR 1.2 (95%CI 0.82–1.8) and HR 1.3
(95%CI 0.81–2.0), respectively P = 0.38). The stratified results of
unadjusted and adjusted HRs for survival are shown in Table 3.
Fig. 2. Kaplan–Meier survival curve and number at risk according to treatment group. Abbreviations: cCHRT ‘concurrent chemoradiation’, sCHRT ‘sequential chemoradiation’,
RT ‘radical radiotherapy’, OS ‘overall survival’.
Table 3









75–79 0.94 (0.50–1.8) 0.86 NA
80+ 1.7 (0.74–3.7) 0.22
WHO PS
0–1 Reference
2–3 1.6 (0.37–6.5) 0.55 NA
Comorbidity
No severe Reference Reference




75–79 0.42 (0.2–0.84) 0.014 0.42 (0.2–0.84) 0.014
80+ 0.94 (0.44–2.0) 0.86 0.89 (0.41–1.9) 0.76
WHO PS
0–1 Reference
2–3 0.91 (0.48–1.7) 0.78 NA
Comorbidity
No severe Reference
Severe 0.76 (0.42–1.4) 0.35 NA
Figures are displayed as HR (95%CI) ‘Hazard Ratio (95% Confidence Interval)’,
abbreviations: cCHRT ‘concurrent chemoradiation’, NA ‘Not Applicable’, sCHRT
‘sequential chemoradiation’, WHO PS ‘World Health Organization Performance
Status’, HR > 1.0 indicates worse survival, none of the unadjusted predictors was
significant for radical radiotherapy or no curative treatment.
E.J.M. Driessen et al. / Radiotherapy and Oncology 121 (2016) 26–31 29Among patients receiving cCHRT, those with severe comorbidity
had significant worse (median) survival compared to patients
without severe comorbidity (22 months (95%CI 13–31) and
15 months (95%CI 8.0–22), respectively (P = 0.019) and HR 2.0(95%CI 1.1–3.5)). Survival for patients aged 75–79 receiving sCHRT
was superior compared to ages 70–74 (HR 0.42 (95%CI 0.21–0.84)).
The number of comorbid conditions was not associated with worse
survival for both cCHRT and sCHRT. For RT and no curative treat-
ment, none of the patient characteristics were associated with
superior or worse survival. As >60% of patients had two or more
mild, moderate or severe comorbid conditions, types of comorbid-
ity were not included into multivariate analyses.Discussion
This study aimed to evaluate administered treatment, motives
for omitting cCHRT and predictors for treatment tolerance and sur-
vival in unselected elderly patients with unresectable stage III
NSCLC in daily clinical practice. The most common motives for
omitting cCHRT were comorbidity and/or poor PS and patient refu-
sal. Worse treatment tolerance and survival were found for severe
comorbidity and survival was not significantly superior for cCHRT
compared to sCHRT or RT.
The proportion of patients receiving cCHRT (33%) was compara-
ble to other elderly-specific studies (33–41%) [14,22] and less often
administered to patients aged P75 with PSP 2 and severe comor-
bidity. Both PS and comorbidity are important indications for treat-
ment toxicity and survival as reflected by the most common
motives for omitting cCHRT and should be analyzed carefully
before treatment decision-making [5,7,9,21]. Not choosing inten-
sive treatment could originate from cherishing a good QoL instead
of longer survival time at the end of life [7,11].
Toxicity rates are generally higher in unselected patients com-
pared to selected patients in clinical trials [19]. PS, comorbidity
and age could be predictors for treatment toxicity [31,32].
Presumably, PS is a stronger and more robust risk factor than
30 Treatment effects in stage III NSCLC P70comorbidity due to assessment at diagnosis [7,21]. However, ACE-
27 can provide more detailed information to distinguish patients
eligible for cCHRT or sCHRT due to a time window of events and
severity of organ decompensation [17,21,29,33]. In the present
study, severe comorbidity (P1 severe or P2 moderate decompen-
sations) and P2 comorbid conditions indicated worse treatment
tolerance for cCHRT and sCHRT (unplanned hospitalizations and/
or not completing treatment). COPD (Chronic Obstructive Pul-
monary Disease) is common among NSCLC-patients and can
increase pulmonary toxicity when treated intensively [23].
Although the number of comorbid conditions is easier to use dur-
ing clinical evaluation, investigating severity of comorbidity is
preferable since it can be informative for both treatment tolerance
and survival. Radiation esophagitis is common as well, especially
for cCHRT, and may result in hospitalization, treatment interrup-
tion and worse treatment outcomes [34,35]. Despite that hospital-
izations were common for CHRT, the majority completed
treatment as proper symptom management was applied. Radio-
therapy technique can be related to treatment completion and tol-
erance [34,35]. Despite of changes in techniques during this cohort,
tolerance outcomes were not significantly different through
included years (P = 0.95). Since dose volume data for organs at risk
were not available, it remains uncertain whether synergistic effects
of comorbidity, organ dose volumes, radiation esophagitis and
other adverse events decreased treatment tolerance in multi-
modality treatment [36–38].
Median survival after cCHRT was not significantly superior
compared to sCHRT or RT. This is in contrast to a meta-analysis
and population-based study in which survival was superior for
cCHRT compared to sCHRT. Although this might be explained by
lack of power in the current study, this could also be due to the fact
that only younger patients and/or fit elderly were included which
does not represent daily practice [1,2]. Older patients are often
treated less aggressive because of toxicity risk and potential worse
survival [14,15,21]. On the contrary, patients aged 75–79 years
receiving sCHRT had better survival compared to ages 70–74. This
is probably due to selection of the fittest elderly and can indicate
that functional age instead of high age provides a broader view
on possible treatment tolerance and survival [32]. PS was not
found to be a significant predictor for survival in multivariate anal-
yses. Scoring of PS is physician dependent and therefore could be
more subjective. Also, correcting for two strongly related outcomes
like PS and comorbidity in a multivariate model can lead to inclu-
sion of the most explanatory only [21], which would be comorbid-
ity in this case. In case of cCHRT, severe comorbidity was predictive
for worse treatment tolerance and worse median survival com-
pared to no severe comorbidity. The Raditux trial also found
shorter survival in case of cCHRT and comorbidity and indicated
the need for studies investigating (severe) comorbidity and treat-
ment outcomes [23]. Possibly, worse survival for cCHRT could also
be explained by poor-risk patients receiving carboplatin more
often and higher survival rates can be reached in selected patients
receiving cisplatin [39]. Due to minor differences in survival and
less adverse events, it can be suggested that sCHRT is more feasible
than cCHRT in unselected elderly [4] and RT remains an alternative
for CHRT in patients with severe comorbidity [9,10]. However,
cCHRT should not be denied to selected elderly patients
[14,19,40]. The strengths of our study are the high external validity
and patient inclusion between 2009 and 2013. This provides fairly
recent and demonstrative patient data which are generalizable to
other unselected elderly NSCLC patients. Data quality and com-
pleteness were good since both medical files and the Netherlands
Cancer Registry were used for retrieval. In addition, all patients
were diagnosed and staged completely, including PET/CT. A weak-
ness of this study is that due to the retrospective observational
design, physicians selected the best suitable therapy for the patientand randomization has not been performed. However, analyses
were stratified to take into account ‘confounding by indication’.
Some data regarding social factors were incomplete and could
not be included in the analyses. A formal geriatric assessment is
not included in standard care, and as such, we could not include
extensive geriatric characteristics or a weighted geriatric score.
An explanation for not detecting significant differences between
curative options could be lack of statistical power, as the number
of patients required for detecting a significant and clinically mean-
ingful difference for survival could not be included (>100 per treat-
ment arm). Also, median FU was shorter for cCHRT (35 months)
compared to sCHRT (62 months) and RT (47 months) and a rela-
tively high proportion of patients receiving cCHRT was still alive
at the end of the study period and censored. This might explain
why long-term superiority of cCHRT over sCHRT for the elderly
could not yet be supported. Although this study was underpow-
ered and conclusions should be drawn carefully, the negative
impact of comorbidity on treatment tolerance and survival is
potentially true.
Especially for the elderly, the goals and preferences of the patient
regarding survival, QoL and tolerance of treatment are important to
take into consideration in multidisciplinary decision-making.
Consequently, there is a need for elderly-specific prospective
observational studies addressing patient preferences, the role of
severe comorbidity in treatment tolerance and survival and the
probable survival benefit of cCHRT compared to both sCHRT and
RT [10]. Comprehensive Geriatric Assessments (GCA) should be
included to examine geriatric characteristics and QoL during and
after treatment, in order to provide a weighted score for geriatric
characteristics to assess treatment outcomes and provide the best
suitable treatment for each patient [13,14,32,33]. These issues are
largely addressed in the prospective randomized trial ELDAPT
(NCT02284308), which has started recently in the Netherlands.
The results of ELDAPT can facilitate treatment decision making
since patient preferences and capacities can be collected more
precisely and interpreted in the light of a geriatric view [7,33].
In conclusion, comorbidity, poor PS and patient refusal were the
most common motives for omitting cCHRT. Despite the fact that
relatively fit and younger elderly were assigned to cCHRT, treat-
ment tolerance was worse for patients receiving cCHRT, especially
for those with severe comorbidity. Only minor differences in sur-
vival between cCHRT, sCHRT and RT were found. This means that
sCHRT or RT might be more feasible treatment options for the
elderly. Future prospective studies should focus on patient prefer-
ences, (severe) comorbidity, predictive geriatric characteristics and
include quality of life or functionality as important end points. As a
result, more evidence can be gathered for treatment decisions in
elderly patients with unresectable NSCLC, leading to the most opti-
mal balance between quality of life and survival.Conflict of interest statement
None declared.Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.radonc.2016.07.
025.
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